[go: up one dir, main page]

MX2020001732A - Tratamiento de las afecciones del sistema nervioso central. - Google Patents

Tratamiento de las afecciones del sistema nervioso central.

Info

Publication number
MX2020001732A
MX2020001732A MX2020001732A MX2020001732A MX2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A
Authority
MX
Mexico
Prior art keywords
disorders
treatment
nervous system
central nervous
mammal
Prior art date
Application number
MX2020001732A
Other languages
English (en)
Inventor
Nishi Toshiya
Kondo Shinichi
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020001732A publication Critical patent/MX2020001732A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Los aspectos de la presente invención se refieren a un método para tratar una encefalopatía epiléptica en un mamífero en necesidad del mismo, que comprende administrar para al mamífero una composición que comprende una cantidad eficaz de (4-bencil-4-hidroxipiperidin-1-il) (2,4´-bipiridina-3-il)metanona o una sal farmacéuticamente aceptable de la misma.
MX2020001732A 2017-08-31 2018-08-30 Tratamiento de las afecciones del sistema nervioso central. MX2020001732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762553070P 2017-08-31 2017-08-31
PCT/JP2018/032949 WO2019045121A1 (en) 2017-08-31 2018-08-30 TREATMENT OF CNS DISEASES

Publications (1)

Publication Number Publication Date
MX2020001732A true MX2020001732A (es) 2020-03-20

Family

ID=63722720

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001732A MX2020001732A (es) 2017-08-31 2018-08-30 Tratamiento de las afecciones del sistema nervioso central.

Country Status (8)

Country Link
US (4) US11285139B2 (es)
EP (1) EP3675852A1 (es)
JP (2) JP7196157B2 (es)
KR (1) KR102680786B1 (es)
CN (2) CN111065394B (es)
CA (1) CA3073925A1 (es)
MX (1) MX2020001732A (es)
WO (1) WO2019045121A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2766380B1 (en) 2011-10-14 2019-04-24 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
RU2019126333A (ru) 2013-04-17 2019-10-08 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
MX362543B (es) 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
RS60642B1 (sr) 2014-10-16 2020-09-30 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
TW202426002A (zh) 2014-10-16 2024-07-01 美商賽吉醫療公司 用於治療中樞神經系統(cns)病症之組合物及方法
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
DK3250210T3 (da) 2015-01-26 2021-03-08 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
EP3481844B1 (en) 2016-07-11 2024-04-17 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CN116162121A (zh) 2016-07-11 2023-05-26 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
CN115974955A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
BR112020009265A2 (pt) 2017-11-14 2020-10-20 Sk Biopharmaceuticals Co., Ltd. medicamento e composição farmacêutica para a prevenção, alívio ou tratamento de crise de ausência ou epilepsia que apresenta crise de ausência, uso de um composto de carbamato ou um sal, solvato ou hidrato do mesmo, e, método para prevenir, aliviar ou tratar crise de ausência ou epilepsia que apresenta crise de ausência.
WO2020021372A1 (en) * 2018-07-24 2020-01-30 Zenvision Pharma Llp Nasal drug delivery system of brivaracetam or salt thereof thereof
GB2580881A (en) * 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
PH12021553005A1 (en) 2019-05-31 2023-08-14 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
WO2021110574A1 (en) * 2019-12-02 2021-06-10 F. Hoffmann-La Roche Ag Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors
GB2597311A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597312A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597285A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
US20240197704A1 (en) * 2021-04-09 2024-06-20 Johns Hopkins University Treatment methods and compositions comprising perampanel
CN115487144A (zh) * 2021-06-18 2022-12-20 北京万全德众医药生物技术有限公司 一种卢非酰胺的口服液制备方法
WO2023175591A1 (en) * 2022-03-18 2023-09-21 Takeda Pharmaceutical Company Limited Methods of treating neurological diseases
WO2024100531A1 (en) * 2022-11-07 2024-05-16 Takeda Pharmaceutical Company Limited Method of treating seizure disorders
WO2025126159A1 (en) * 2023-12-15 2025-06-19 Takeda Pharmaceutical Company Limited A method for treating a neurological disease in a recreational drug user
WO2025257799A1 (en) * 2024-06-14 2025-12-18 Takeda Pharmaceutical Company Limited Methods of treating dravet syndrome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2763979T (pt) 2011-10-07 2019-04-12 Takeda Pharmaceuticals Co Compostos de 1-arilcarbonil-4-oxi-piperidina úteis para o tratamento de doenças neurodegenerativas
MX2015007495A (es) 2012-12-11 2015-09-04 Takeda Pharmaceutical Compuesto heterociclico.
EP2982666B1 (en) 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017065287A1 (ja) 2015-10-16 2017-04-20 武田薬品工業株式会社 複素環化合物の製造方法

Also Published As

Publication number Publication date
CN116370475A (zh) 2023-07-04
JP2023027267A (ja) 2023-03-01
CA3073925A1 (en) 2019-03-07
KR20200046022A (ko) 2020-05-06
KR102680786B1 (ko) 2024-07-02
US11285139B2 (en) 2022-03-29
JP7469445B2 (ja) 2024-04-16
US20200306238A1 (en) 2020-10-01
US20220168294A1 (en) 2022-06-02
JP2020532508A (ja) 2020-11-12
US20250281477A1 (en) 2025-09-11
CN111065394A (zh) 2020-04-24
WO2019045121A1 (en) 2019-03-07
JP7196157B2 (ja) 2022-12-26
EP3675852A1 (en) 2020-07-08
US20230087903A1 (en) 2023-03-23
CN111065394B (zh) 2023-03-31

Similar Documents

Publication Publication Date Title
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
CL2023000095A1 (es) Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
CO2019001625A2 (es) Compuestos de captura de aldehído y usos de los mismos
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
CR20190468A (es) Métodos para tratar enfermedades y trastornos mediados por completo
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
AR101740A1 (es) Terapia de combinación y composiciones
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
CO2018009559A2 (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
MX389545B (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
MX2018003023A (es) Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
MX2016010085A (es) Metodos para tratar lesion del cerebro leve.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
CL2021000743A1 (es) Métodos para tratar trastornos mieloproliferativos
MX2018001684A (es) Metodo de curacion de heridas.
MX2017003140A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.